Brief: Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy Bodies
04/03/2026 12:33
March 4 (Reuters) - CervoMed Inc CRVO.O: CERVOMED ANNOUNCES SELECTION OF FORMULATION AND DOSING REGIMEN FOR PLANNED PHASE 3 TRIAL IN PATIENTS WITH DEMENTIA WITH LEWY BODIES CERVOMED INC - TO INITIATE GLOBAL PHASE 3 TRIAL IN DLB IN SECOND HALF OF 2026 Source text: ID:nGNX1Jtn5D Further company coverage: CRVO.O ((Reuters.Briefs@thomsonreuters.com;))